Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study

Abstract

This study shows that among hospitalized patients with SARS-CoV-2 Omicron variant infection at risk of disease progression, treatment with sotrovimab alone or in combination with remdesivir did not decrease in-hospital mortality. These real-world clinical findings in combination with previous in vitro data about lacking neutralizing activity of sotrovimab against SARS-CoV-2 Omicron variant do not support sotrovimab as a treatment option in these patients.

Sotrovimab for the Treatment of COVID-19

“…In the single-centre, retrospective, matched cohort study by Woo et al (2022), 26 the only outcome measure was the in-hospital mortality rate. The follow-up period post-treatment was not reported.…”

“…No potentially relevant publications were retrieved from the grey literature search for full-text review. Of the 12 potentially relevant articles, 8 were excluded for various reasons (i.e., irrelevant population or no comparator), and 4 publications [26][27][28][29] met the selection criteria and were included in this report. Non-peer-reviewed preprints were not considered for this report.…”

“…Three nonrandomized retrospective studies [26][27][28] and 1 nonrandomized prospective study 29 reporting the clinical effectiveness of sotrovimab in patients with confirmed COVID-19 during the surge of Omicron subvariants were included in this report.…”

“…The 3 retrospective studies were conducted by authors based in the UK, 28 Germany, 26 and Qatar, 27 and the prospective study 29 was conducted by authors based in Italy.…”

“…In the single-centre, retrospective, matched cohort study by Woo et al (2022), 26 the authors aimed to investigate in-hospital mortality for patients with Omicron subvariants who were treated with sotrovimab, with or without remdesivir, compared to matched control groups who did not receive treatment. Treatment regimens were either a single 500 mg IV infusion of sotrovimab, or a single 500 mg IV infusion of sotrovimab combined with a 3-day course of remdesivir (200 mg on day 1, followed by 100 mg daily on days 2 and 3).…”